# US 2014/0154222 A1 · Isolated cells and populations comprising same for the treatment of cns diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154222 A1
- Document ID: US20140154222A1
- Status: Published application
- Kind: A1
- Application number: 14/173,846
- Filed: 2014-02-06
- Published: 2014-06-05
- Earliest claimed: 2006-06-18
- Assignees: Ramot at Tel-Aviv University Ltd.
- Applicants: Ramot at Tel-Aviv University Ltd.
- Inventors: Daniel OFFEN; Merav Bahat-Stromza; Eldad Melamed
- Web page: https://patentgrep.com/patent/US20140154222A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/40: Regulators of development
- C12N 2506/1353: from bone marrow mesenchymal stem cells (BM-MSC)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.

## Claims

### Claim 1

A non-genetically modified isolated human cell which expresses CD90, expresses glial fibrillary acidic protein (GFAP) and secretes at least one neurotrophic factor, wherein a secretion of said neurotrophic factor is at least 2 times greater than a basal secretion of said neurotrophic factor in a non-differentiated mesenchymal stem cell.

### Claim 2 (depends on 1)

The isolated human cell of claim 1, having been differentiated ex vivo from a human mesenchymal stem cell.

### Claim 3 (depends on 1)

The isolated human cell of claim 1, wherein a secretion of said neurotrophic factor is at least 5 times greater than a basal secretion of said neurotrophic factor in said non-differentiated mesenchymal stem cell.

### Claim 4 (depends on 1)

The isolated human cell of claim 1, having a star-shaped body.

### Claim 5 (depends on 1)

The isolated human cell of claim 1, wherein said at least one neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5, Neurturin (NTN), Persephin, brain derived neurotrophic factor (BDNF), artemin (ART), ciliary neurotrophic factor (CNTF), insulin growth factor-I (IGF-1) and Neublastin.

### Claim 6 (depends on 5)

The isolated human cell of claim 5, wherein said at least one neurotrophic factor is GDNF.

### Claim 7 (depends on 6)

The isolated human cell of claim 6, wherein a secretion of said GDNF is upregulated by IL-1 beta and/or cabergoline.

### Claim 8 (depends on 1)

A method of treating a CNS disease or disorder comprising administering to an individual in need thereof a therapeutically effective amount of a population of the cells of claim 1, thereby treating the CNS disease or disorder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the CNS disease or disorder is a neurodegenerative disease or disorder.

### Claim 10 (depends on 8)

The method of claim 8, wherein the CNS disease or disorder is selected from the group consisting of a motion disorder, a dissociative disorder, a mood disorder, an affective disorder, an addictive disorder and a convulsive disorder.

### Claim 11 (depends on 9)

The method of claim 9, wherein the neurodegenerative disorder is selected from the group consisting of Parkinson's, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease and Huntingdon's disease.

### Claim 12 (depends on 8)

The method of claim 8, wherein said cells are autologous cells.

### Claim 13 (depends on 8)

The method of claim 8, wherein said cells are non-autologous cells.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising as an active agent a population of the cells of claim 1, and a pharmaceutically acceptable carrier.